The British Journal of Psychiatry 170: 345-350 (1997)
© 1997 The Royal College of Psychiatrists

Controlled efficacy study of fluoxetine in dysthymia

JM Vanelle, D Attar-Levy, MF Poirier, M Bouhassira, P Blin and JP Olie
Service Hospitalo-Universitaire de Sante Mentale et de Therapeutique, Centre Hospitalier Sainte Anne, Paris, France.

BACKGROUND: There have been very few controlled studies of antidepressants in dysthymia, particularly in samples diagnosed reliably and with an adequate length of follow-up. In this investigation, we measured the long-term outcome in a large group of patients meeting DSM-III-R criteria for dysthymia. This study was designed to investigate whether fluoxetine is effective in the treatment of dysthymia. METHOD: This randomised study including 140 patients, compared fluoxetine (91 patients) and placebo (49 patients) on a double-blind basis in two distinct phases: a short-term end-point (3 months with 20 mg/day fluoxetine) and a medium-term end-point (6 months) where the initial responders continued double-blind treatment unchanged and non-responders received an additional treatment of 20 mg/day fluoxetine. RESULTS: After three months of treatment, response was seen more frequently in the fluoxetine group (42/72) than in the placebo group (14/39, P < 0.0001). Improved patients at 3 months were still improved at 6 months. Furthermore, 50% of the nonresponders at 3 months improved and rated as responders at 6 months, after fluoxetine was increased to 40 mg daily. CONCLUSIONS: This study showed the significant and persistent action of fluoxetine on dysthymia. The finding that 50% of the non-responders at 3 months were improved at 6 months, after fluoxetine dosage was increased to 40 mg daily, argues in favour of treating dysthymic patients for at least 6 months, and with a higher dosage if the initial doses are ineffective.

This article has been cited by other articles:

				A. Qaseem, V. Snow, T. D. Denberg, M. A. Forciea, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee Using Second-Generation Antidepressants to Treat Depressive Disorders: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, November 18, 2008; 149(10): 725 - 733. [Abstract] [Full Text] [PDF]

				G. Gartlehner, B. N. Gaynes, R. A. Hansen, P. Thieda, A. DeVeaugh-Geiss, E. E. Krebs, C. G. Moore, L. Morgan, and K. N. Lohr Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians Ann Intern Med, November 18, 2008; 149(10): 734 - 750. [Abstract] [Full Text] [PDF]

				D. P. Devanand, N. Juszczak, M. S. Nobler, N. Turret, L. Fitzsimons, H. A. Sackeim, and S. P. Roose An Open Treatment Trial of Venlafaxine for Elderly Patients With Dysthymic Disorder J Geriatr Psychiatry Neurol, December 1, 2004; 17(4): 219 - 224. [Abstract] [PDF]

				A. S. Young, R. Klap, C. D. Sherbourne, and K. B. Wells The Quality of Care for Depressive and Anxiety Disorders in the United States Arch Gen Psychiatry, January 1, 2001; 58(1): 55 - 61. [Abstract] [Full Text] [PDF]

				J. W. Williams Jr., C. D. Mulrow, E. Chiquette, P. H. Noel, C. Aguilar, and J. Cornell A Systematic Review of Newer Pharmacotherapies for Depression in Adults: Evidence Report Summary: Clinical Guideline, Part 2 Ann Intern Med, May 2, 2000; 132(9): 743 - 756. [Abstract] [Full Text] [PDF]

				P. J. Goodnick and B. J. Goldstein Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life J Psychopharmacol, January 1, 1998; 12(4_suppl): S21 - S54. [Abstract] [PDF]

				Dysthymia: Treatment with Fluoxetine Journal Watch Women's Health, June 1, 1997; 1997(601): 20 - 20. [Full Text]